Geneva Partners LLC Has $981,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Geneva Partners LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 79.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 11,405 shares of the company’s stock after selling 43,602 shares during the quarter. Geneva Partners LLC’s holdings in Novo Nordisk A/S were worth $981,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $42,000. Albion Financial Group UT boosted its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares during the period. Sound Income Strategies LLC raised its holdings in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after acquiring an additional 243 shares during the period. Finally, Hager Investment Management Services LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $46,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $85.83 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a market cap of $385.16 billion, a price-to-earnings ratio of 27.78, a PEG ratio of 0.93 and a beta of 0.45. The firm has a 50 day simple moving average of $92.24 and a 200 day simple moving average of $112.01.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. Research analysts predict that Novo Nordisk A/S will post 3.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVO. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.